Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

BIOMARIN PHARMACEUTICAL INC

Form 4 May 17, 2016

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

if no longer subject to Section 16. Form 4 or

Check this box

Expires: January 31, 2005

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per response... 0.5

5. Relationship of Reporting Person(s) to

Form 5 obligations may continue. *See* Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

2. Issuer Name and Ticker or Trading

ion 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

BAFFI ROI	BERT		ARIN PHARMACEUTICAL BMRN]	(Check all applicable)						
(Last) C/O BIOMA	ARIN	(Month/ 05/13/2	of Earliest Transaction Day/Year) 2016	Director 10% OwnerX Officer (give title Other (specify below) EVP, Technical Operations						
PHARMACEUTICAL INC., 770 LINDARO ST.										
LINDARO	(Street)		endment, Date Original onth/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person						
SAN RAFAEL, CA 94901 — Form filed by More than One Reporting Person										
(City)	(State)	(Zip) Tak	ole I - Non-Derivative Securities Acc	quired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5)	5. Amount of Securities Form: Direct Indirect Beneficially (D) or Beneficial Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported						
			or Code V Amount (D) Price	Transaction(s) (Instr. 3 and 4)						
Common Stock	05/13/2016	05/13/2016	F 1,566 D \$82.71	135,386 D						
Common Stock				Shares held by 31,676 I Baffi Family						

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Trust

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transactio	5. orNumber	6. Date Exerc Expiration D		7. Title an Amount o		
Security (Instr. 3)	or Exercise Price of Derivative Security	of ative	•	Code (Instr. 8)	of (Month/Day/Ye Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			Underlying Securities (Instr. 3 and 4)	Security (Instr. 5	y Secur
				Code V	(A) (D)	Date Exercisable	Expiration Date	or Title Numof	mber ares	

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BAFFI ROBERT C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901

EVP, Technical Operations

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact

05/17/2016

Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2